// App-Quantinova.ai

: Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study.

Researchers

Presenter

  • Claudia A.M. Fulgenzi

Principal Investigators

  • Cian Murphy

  • Antonio D'Alessio

  • Bernhard Scheiner

  • Matthias Pinter

  • Alessio Cortellini

  • David J. James Pinato

Medical Centers

  • Department of Surgery & Cancer, Imperial College London, London, United Kingdom

  • Medical University of Vienna, Vienna, Austria

  • Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

  • Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

  • Imperial College, London, United Kingdom

  • Department of Surgery & Cancer, Imperial College London, London, United Kingdom

Locations

  • Austria

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Infectious Diseases (ID)

Disease

  • Systemic inflammation

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved